Literature DB >> 15870560

Adenomyosis: what is the impact on fertility?

Ioannis M Matalliotakis1, Ilias K Katsikis, Dimitrios K Panidis.   

Abstract

PURPOSE OF REVIEW: This review is timely and relevant for several reasons. The incidence of adenomyosis begins to rise from the mid-thirties. Moreover, more women are delaying their first pregnancy until later in their thirties or forties, and consequently adenomyosis is encountered more frequently in the fertility clinic during diagnostic work-up. Furthermore, it is difficult to diagnose adenomyosis before surgery, because there are no pathognomonic signs, symptoms or physical findings. Finally, reference data are very limited. RECENT
FINDINGS: This review refers to adenomyosis of the uterus as a factor in female infertility. The clinical presentation of adenomyosis uteri is also reviewed, as well as animal and human studies concerning the effect of adenomyosis in female infertility. Different treatment options are discussed, especially those referring to patients who wish to maintain their fecundity.
SUMMARY: Uterine adenomyosis remains a fairly frequent and debilitating disease that will be encountered with increasing incidence in the infertile female population. While spectacular advances have been made in recent years in the non-invasive diagnosis of the condition, non-surgical treatment options for infertile patients with adenomyosis arise but need to be confirmed in larger series.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870560     DOI: 10.1097/01.gco.0000169103.85128.c0

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  10 in total

1.  A case-control investigation of adenomyosis: impact of control group selection on risk factor strength.

Authors:  Britton Trabert; Noel S Weiss; Carole B Rudra; Delia Scholes; Victoria L Holt
Journal:  Womens Health Issues       Date:  2011-01-26

2.  Neurotrophin expression is not affected in uteri of women with adenomyosis.

Authors:  Maria Luisa Barcena de Arellano; Melanie Franziska Wagner; Jeannette Oldeweme; Julia Arnold; Andreas Ebert; Achim Schneider; Sylvia Mechsner
Journal:  J Mol Neurosci       Date:  2012-03-28       Impact factor: 3.444

3.  Adenomyosis a variant, not a disease? Evidence from hysterectomized menopausal women in the Study of Women's Health Across the Nation (SWAN).

Authors:  Gerson Weiss; Priya Maseelall; Laura L Schott; Sarah E Brockwell; Miriam Schocken; Janet M Johnston
Journal:  Fertil Steril       Date:  2008-02-20       Impact factor: 7.329

4.  β-Catenin activation contributes to the pathogenesis of adenomyosis through epithelial-mesenchymal transition.

Authors:  Seo Jin Oh; Jung-Ho Shin; Tae Hoon Kim; Hee Sun Lee; Jung-Yoon Yoo; Ji Yeon Ahn; Russell R Broaddus; Makoto M Taketo; John P Lydon; Richard E Leach; Bruce A Lessey; Asgerally T Fazleabas; Jeong Mook Lim; Jae-Wook Jeong
Journal:  J Pathol       Date:  2013-10       Impact factor: 7.996

Review 5.  Myomas and Adenomyosis: Impact on Reproductive Outcome.

Authors:  Nikos F Vlahos; Theodoros D Theodoridis; George A Partsinevelos
Journal:  Biomed Res Int       Date:  2017-11-06       Impact factor: 3.411

6.  GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity.

Authors:  Song Guo; Zhichao Li; Li Yan; Yijuan Sun; Yun Feng
Journal:  Drug Des Devel Ther       Date:  2018-06-07       Impact factor: 4.162

7.  Ultrasound diagnosis of adenomyosis, leiomyoma, or combined with histopathological correlation.

Authors:  Magdi Hanafi
Journal:  J Hum Reprod Sci       Date:  2013-07

8.  Norethindrone acetate in the medical management of adenomyosis.

Authors:  Ozgul Muneyyirci-Delale; Ashadeep Chandrareddy; Siddhi Mankame; Nanna Osei-Tutu; Hans von Gizycki
Journal:  Pharmaceuticals (Basel)       Date:  2012-10-22

9.  Triptorelin for the treatment of adenomyosis: A multicenter observational study of 465 women in Russia.

Authors:  Elena Andreeva; Yulia Absatarova
Journal:  Int J Gynaecol Obstet       Date:  2020-09-19       Impact factor: 3.561

10.  Ultra-Long GnRH Agonist Protocol During IVF/ICSI Improves Pregnancy Outcomes in Women With Adenomyosis: A Retrospective Cohort Study.

Authors:  Jie Lan; Yaoqiu Wu; Zexuan Wu; Yingchen Wu; Rong Yang; Ying Liu; Haiyan Lin; Xuedan Jiao; Qingxue Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-31       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.